FTH

SEC source: 0001567619-22-004779 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,188,337

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.20 to $4.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-004777 · doc1.xml · nonDerivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,188,337

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.20 to $4.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-22-010982 · doc4.xml · derivative · entry 2

Pierce Robert Hamilton · CIK 0001594129 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,000

Underlying: Common Stock · 62,000 shares

Expires 2032-02-14

F2 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2023; and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001209191-22-010982 · doc4.xml · nonDerivative · entry 1

Pierce Robert Hamilton · CIK 0001594129 · Chief R&D Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,000

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2023, February 15, 2024, February 15, 2025 and February 15, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001209191-22-010976 · doc4.xml · derivative · entry 2

Celebi John · CIK 0001843539 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,600

Underlying: Common Stock · 161,600 shares

Expires 2032-02-14

F3 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2023; and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001209191-22-010976 · doc4.xml · nonDerivative · entry 1

Celebi John · CIK 0001843539 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,114

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2023, February 15, 2024, February 15, 2025 and February 15, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date.

F2 · balance_after: Includes 214 shares acquired by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan.

SEC source: 0001209191-22-010978 · doc4.xml · derivative · entry 2

Colgan Erin · CIK 0001843563 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,000

Underlying: Common Stock · 62,000 shares

Expires 2032-02-14

F3 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2023; and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001209191-22-010978 · doc4.xml · nonDerivative · entry 1

Colgan Erin · CIK 0001843563 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,686

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2023, February 15, 2024, February 15, 2025 and February 15, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date.

F2 · balance_after: Includes 686 shares acquired by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan.

SEC source: 0001567619-22-004779 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,185,786

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.10 to $4.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-004777 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,185,786

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.10 to $4.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-004543 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,175,786

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.30 to $4.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-004545 · doc1.xml · nonDerivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,175,786

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.30 to $4.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-004543 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,163,286

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.55 to $4.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-004545 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,163,286

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.55 to $4.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-002937 · doc1.xml · nonDerivative · entry 3

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,158,286

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.25 to $4.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-002935 · doc1.xml · nonDerivative · entry 3

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,158,286

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.25 to $4.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-002937 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,148,286

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-002935 · doc1.xml · nonDerivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,148,286

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-002937 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,145,786

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.50 to $4.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-002935 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,145,786

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.50 to $4.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-002036 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,128,286

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.15 to $4.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-002034 · doc1.xml · nonDerivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,128,286

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.15 to $4.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-002036 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,119,386

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.25 to $4.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-002034 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 5,119,386

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.25 to $4.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001804 · doc1.xml · nonDerivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 5,113,286

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.50 to $4.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001801 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,113,286

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.50 to $4.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001804 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 5,083,386

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.75 to $4.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001801 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,083,386

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.75 to $4.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001634 · doc1.xml · nonDerivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 5,063,286

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.60 to $4.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001632 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,063,286

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.60 to $4.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001634 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 5,040,579

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.80 to $5.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001632 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,040,579

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.80 to $5.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001464 · doc1.xml · nonDerivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 5,015,876

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.10 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001462 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,015,876

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.10 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001464 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,995,876

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.90 to $5.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001462 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,995,876

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.90 to $5.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001340 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,985,632

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.05 to $5.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001342 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,985,632

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.05 to $5.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001228 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,975,632

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.95 to $5.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001230 · doc1.xml · nonDerivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,975,632

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.95 to $5.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001228 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,969,413

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.05 to $5.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001230 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,969,413

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.05 to $5.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001165 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,949,460

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.20 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001167 · doc1.xml · nonDerivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,949,460

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.20 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001165 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,940,258

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.10 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001167 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,940,258

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.10 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001007 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,929,413

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.25 to $5.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001003 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,929,413

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.25 to $5.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-000008 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,919,413

F1 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-000006 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,919,413

F1 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.